Atrial fibrillation (AF) is a common but often undiagnosed condition, with prevalence in the United States projected to increase from 5.2 million in 2010 to 12.1 million cases by 2030. AF may present with a wide range of symptoms or may be asymptomatic. Even when asymptomatic, AF increases the risk of stroke or systemic thromboembolism and all-cause mortality compared to no AF. Screening patients at-risk for AF can facilitate detection of AF and allow for initiation of potentially life-saving stroke preventive therapy. New technologies such as photoplethysmography via smartwatch, blood pressure monitors, handheld or smartphone-compatible ECG recorder, and patch ECG monitors offer many options to enable remote detection of undiagnosed AF.
The first episode of this CME Outfitters BriefCase series will focus on AF screening techniques and tools and how best to utilize them when providing care via telemedicine.
At the end of this CME/CE activity, participants should be able to evaluate digital tools that aid in identifying undiagnosed NVAF when providing care via telemedicine.
The following learning objectives pertain only to those requesting CNE or CPE credit: Evaluate digital tools that aid in identifying undiagnosed NVAF for providing care via telemedicine.
Supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.
Primary care physicians, cardiologists, PAs, nurse practitioners, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Turakhia reports that he receives grants from the American Heart Association; Apple Inc.; Bayer; Boehringer Ingelheim; Bristol Myers Squibb Company; Cardiva Medical, Inc.; Janssen Pharmaceuticals, Inc.; and SentreHEART, Inc. He is a consultant for Abbott; BIOTRONIK, Inc.; Cardiva Medical, Inc.; iRhythm Technologies, Inc.; Johnson & Johnson; Medtronic; Milestone Pharmaceuticals, Inc.; MyoKardia, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and Sanofi. He receives other financial or material support as an editor for JAMA Cardiology.
Dr. Tarakji reports that he is a consultant for AliveCor, Inc.; Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc.; and Medtronic.
Dr. Savoy has no disclosures to report.
Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Maria Glukhovsky, PharmD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-110-H01-P
Call us at (877) CME-PROS or (877) 263-7767.